Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer

In women with metastatic breast cancer (MBC), introduction of the anti-HER2 (human epidermal growth factor receptor-2) directed therapies including trastuzumab, pertuzumab, lapatinib, and/or trastuzumab-DM1 has markedly improved overall survival. However, not all cases of HER2-positive breast tumour...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Park, Yeon Hee, Shin, Hyun-Tae, Jung, Hae Hyun, Choi, Yoon-La, Ahn, TaeJin, Park, Kyunghee, Lee, Aeri, Do, In-Gu, Kim, Ji-Yeon, Ahn, Jin Seok, Park, Woong-Yang, Im, Young-Hyuck
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2015
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741657/
https://ncbi.nlm.nih.gov/pubmed/26397225
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים